User menu

Hépatopathie non alcoolique: de la stéatose à la cirrhose

Bibliographic reference Leclercq, Isabelle ; Sempoux, Christine. Hépatopathie non alcoolique: de la stéatose à la cirrhose. In: Acta Endoscopica, Vol. 36, no. 3, p. 299-314 (2006)
Permanent URL
  1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55(7): 434–8.
  2. Bacon Bruce R., Farahvash Mohammad J., Janney Christine G., Neuschwander-Tetri Brent A., Nonalcoholic steatohepatitis: An expanded clinical entity, 10.1016/0016-5085(94)90235-6
  3. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005; 42(5): 987–1000.
  4. McCullough A. The epidemilogy and risk factors of NASH. Fatty liver disease: NASH and related disorders Blackwell Publishing 2004; (Chapter 3): 23–37.
  5. Daniel S, Ben Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999; 94(10): 3010–14.
  6. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 2001; 35(2): 195–9.
  7. Chalasani N, Deeg MA, Persohn S, Crabb DW. Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98(8): 1849–55.
  8. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118(6): 1117–23.
  9. Hilden M, Christoffersen P, Juhl E, Dalgaard JB. Liver histology in a ‘normal’ population-examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 1977; 12(5): 593–7.
  10. Ground KE. Liver pathology in aircrew. Aviat Space Environ Med 1982; 53(1): 14–18.
  11. Marcos A, Fisher RA, Ham JM, Olzinski AT, Shiffman ML, Sanyal AJ et al. Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation 2000; 69(11): 2410–15.
  12. Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121(1): 91–100.
  13. Dixon JB, Bhathal PS, Hughes NR, O’Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004; 39(6): 1647–54.
  14. Silverman Eugene M., Sapala James A., Appelman Henry D., Regression of Hepatic Steatosis in Morbidly Obese Persons After Gastric Bypass, 10.1093/ajcp/104.1.23
  15. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84(5): 1513–17.
  16. Luyckx FH, Desaive C, Thiry A, Dewe W, Scheen AJ, Gielen JE et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998; 22(3): 222–6.
  17. Diehl A.M., Goodman Z., Ishak K.G., Alcohollike liver disease in nonalcoholics, 10.1016/0016-5085(88)90183-7
  18. Hui JM, Kench JG, Chitturi S, Sud A, Farrell GC, Byth K et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38(2): 420–7.
  19. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11(1): 74–80.
  20. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989; 20(6): 594–8.
  21. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30(6): 1356–62.
  22. Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996; 62(12): 1802–05.
  23. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123(1): 134–140.
  24. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35(2): 373–9.
  25. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120(5): 1183–92.
  26. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107(5): 450–5.
  27. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37(4): 917–23.
  28. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121(3): 710–23.
  29. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116(6): 1413–19.
  30. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114(2): 311–18.
  31. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128(2): 343–50.
  32. Huwart L, Peeters F, Sinkus R, Annet L, Salameh N, Ter Beek LC et al. Liver fibrosis: non-invasive assessment with MR elastography. NMR Biomed 2006; 19(2): 173–79.
  33. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37(5): 1202–19.
  34. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24(1): 3–20.
  35. Contos MJ, Choudhury J, Mills AS, Sanyal AJ. The histologic spectrum of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8(3): 481–500.
  36. Gramlich T, Kleiner DE, McCullough AJ, Matteoni CA, Boparai N, Younossi ZM. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol 2004; 35(2): 196–9.
  37. Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004; 40(4): 820–26.
  38. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003; 98(9): 2042–47.
  39. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000; 30(1): 48–53.
  40. Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005; 42(3): 641–9.
  41. Xanthakos S, Miles L, Bucuvalas J, Daniels S, Garcia V, Inge T. Histologic spectrum of nonalcoholic fatty liver disease in morbidly obese adolescents. Clin Gastroenterol Hepatol 2006; 4(2): 226–32.
  42. Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002; 37(1): 154–60.
  43. Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, Degott C et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004; 10(2 Suppl 1): S69-S73.
  44. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut 2002; 50(5): 585–8.
  45. Hubscher SG. Role of liver biopsy in the assessment of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2004; 16(11): 1107–15.
  46. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94(9): 2467–74.
  47. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41(6): 1313–21.
  48. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128(7): 1898–1906.
  49. Goldstein NS, Hastah F, Galan MV, Gordon SC. Fibrosis heterogeneity in nonalcoholic steatohepatitis and hepatitis C virus needle core biopsy specimens. Am J Clin Pathol 2005; 123(3): 382–7.
  50. Garcia-Monzon C, Martin-Perez E, Iacono OL, Fernandez-Bermejo M, Majano PL, Apolinario A et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000; 33(5): 716–24.
  51. Li Z, Diehl AM. Cytokines and inflammatory recruitment in NASH: experimental and human studeis. Fatty liver disease: NASH and related disorders Blackwell Publishing 2004; Chapter 10: 123–31.
  52. Fromenty B, Robin MA, Igoudjil A, Mansouri A, Pessayre D. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab 2004; 30(2): 121–38.
  53. Bass NM, Merriman RB. fatty acid metabolism and lipotoxicity in the pathogenesis of NAFLD/N ASH. Fatty liver disease: NASH and related disorders Blackwell Publishing 2004; chapter 9: 109–22.
  54. Reddy JK. Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2001; 281(6): G1333-G1339.
  55. George J, Pera N, Phung N, Leclercq I, Yun HJ, Farrell G. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 2003; 39(5): 756–64.
  56. Starkel P, Sempoux C, Leclercq I, Herin M, Deby C, Desager JP et al. Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. J Hepatol 2003; 39(4): 538–46.
  57. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18(49): 6853–66.
  58. Leclercq IA, Farrell GC, Sempoux C, Dela PA, Horsmans Y. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol 2004; 41(6): 926–34.
  59. Dela Pena A, Leclercq I, Field J, George J, Jones B, Farrell G. NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 2005; 129(5): 1663–74.
  60. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000; 105(8): 1067–75.
  61. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001; 281(5): G1135-G1139.
  62. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003; 38(1): 123–32.
  63. Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 2004; 39(5): 1286–96.
  64. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106(2): 171–76.
  65. Schattenberg JM, Wang Y, Singh R, Rigoli RM, Czaja MJ. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem 2005; 280(11): 9887–94.
  66. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004; 279(31): 32345–53.
  67. Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 2001; 98(13): 7522–27.
  68. Kraegen EW, Clark PW, Jenkins AB, Daley EA, Chisholm DJ, Storlien LH. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 1991; 40(11): 1397–1403.
  69. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7(8): 941–6.
  70. Friedman JM. The function of leptin in nutrition, weight, and physiology. Nutr Rev 2002; 60(10 Pt 2): S1–14.
  71. Chitturi S, Farrell G, Frost L, Kriketos A, Lin R, Fung C et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002; 36(2): 403–9.
  72. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. Journal of Hepatology 2002; 37(2): 206–213.
  73. Leclercq IA, Horsmans Y. Cell biology of NASH: fibrosis and cell proliferation. Fatty liver disease: NASH and related disorders Blackwell Publishing 2004; chapter 12: 143–158.
  74. Ikejima K, Honda H, Yoshikawa M, Hirose M, Kitamura T, Takei Y et al. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 2001; 34(2): 288–97.
  75. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40(1): 46–54.
  76. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005; 54(1): 117–21.
  77. Tietge UJ, Schmidt HH, Schutz T, Dippe P, Lochs H, Pirlich M. Reduced plasma adiponectin in NASH: central obesity as an underestimated causative risk factor. Hepatology 2005; 41(2): 401–2.
  78. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79–83.
  79. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26(3): 439–51.
  80. Xu Aimin, Wang Yu, Keshaw Hussila, Xu Lance Yi, Lam Karen S.L., Cooper Garth J.S., The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice, 10.1172/jci200317797
  81. Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003; 125(6): 1796–1807.
  82. Neuschwander-Tetri B, Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone, 10.1053/jhep.2003.50420
  83. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39(1): 188–96.
  84. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815–19.
  85. Macda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094–9.
  86. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27(1): 103–7.
  87. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38(2): 413–19.
  88. Nair S, Diehl AM, Wiseman M, Farr GH, Jr., Perrillo RP. Met-formin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20(1): 23–8.
  89. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100(5): 1082–90.
  90. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19(5): 537–44.